Key result
Pemafibrate plus losartan normalizes proteinuria and improves renal echogenicity in normolipidemic LPG.
Why the study?
Lipoprotein glomerulopathy is an apolipoprotein E-related glomerular disease commonly associated with hypertriglyceridemia, while normolipidemic variants are scarce.
Does combined treatment with pemafibrate and losartan improve proteinuria and reduce renal cortical echogenicity in a patient with normolipidemic lipoprotein glomerulopathy?
Case Report (n=1)
No
Does combined treatment with pemafibrate and losartan improve proteinuria and reduce renal cortical echogenicity in a patient with normolipidemic lipoprotein glomerulopathy?
Answers are grounded in this paper and cite their sources.
Combined treatment with pemafibrate and losartan normalized proteinuria and reduced renal cortical echogenicity in a rare case of normolipidemic lipoprotein glomerulopathy, supporting further evaluation of this combination.
Lipoprotein glomerulopathy (LPG) is an apolipoprotein E (ApoE)-related glomerular disease often associated with hypertriglyceridemia, and normolipidemic variants are scarce. Herein, we report a normolipidemic patient with genetically confirmed LPG whose proteinuria normalized during combined treatment with pemafibrate and losartan. A 22-year-old Japanese man was referred for evaluation of persistent proteinuria. Diagnosis was established through a combination of renal biopsy, liquid chromatography-tandem mass spectrometry of laser-microdissected glomeruli from paraffin sections, and direct DNA sequencing of ApoE, which revealed heterozygosity for the ApoE-Sendai mutation (Arg145Pro). At the time of diagnosis, his serum ApoE levels were high, whereas the triglyceride and low-density lipoprotein cholesterol levels remained within the reference ranges. Furthermore, renal ultrasonography revealed increased echogenicity of the renal cortex. Treatment with pemafibrate and losartan was associated with the normalization of proteinuria and a reduction in renal cortical echogenicity. ApoE levels peaked 12 months after treatment initiation and subsequently gradually decreased. This case highlights the importance of considering LPG in patients with persistent proteinuria even when serum lipid levels are normal. The normalization of proteinuria during combined treatment with pemafibrate and losartan supports further evaluation of this combination in patients with normolipidemic LPG. Changes in renal echogenicity may provide additional information during follow-up, although their clinical significance requires further study.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2026) conducted a case report in Normolipidemic lipoprotein glomerulopathy (LPG) (n=1). Pemafibrate and losartan was evaluated on Normalization of proteinuria and reduction in renal cortical echogenicity. Combined pemafibrate and losartan normalized proteinuria and reduced renal cortical echogenicity in 1 patient with normolipidemic LPG, with ApoE levels peaking at 12 months before declining.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: